Pharmaxis Ltd (ASX:PXS) (FRA:UUD) has multiple potential value inflection points over the next two years, with two drugs in clinical trials that are due to report meaningful efficacy and safety endpoints in patients by the end of 2022.
The company has a platform technology that has delivered a pipeline of first in class or best in class clinical drugs for inflammatory and fibrotic diseases. The first of these drugs already has an IND approval from the FDA and is currently being trialled in myelofibrosis patients.
Its lead asset PXS-5505 – with disease-modifying potential in myelofibrosis – is in Phase 1c/2 trial, with further collaborations to extend the value of PXS-5505 in a variety of other oncology indications where there is strong unmet need.
Pharmaxis Ltd announces world-first clinical trial of wound and burn scars prevention treatment proactiveinvestors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com Daily Mail and Mail on Sunday newspapers.